BMYCelgeneFinished
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Follicular Lymphoma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 1,030 (final count)
- Started
- Dec 29, 2011
- Main results expected
- Apr 30, 2024
- Fully finished
- Apr 30, 2024
- Results posted
- May 14, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review
Measured over: At 120 weeks
Progression-free Survival (PFS)
Measured over: From randomization into the study to the first observation of documented disease progression or death due to any cause (up to approximately 140 months).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT01476787 · record last updated 2025-05-14 · checked 2026-11-09 15:47 UTC